Mirabegron reduces urinary frequency and improves overactive bladder symptoms at 3 months after 125I-brachytherapy for prostate cancer: An open-labeled, randomized, non-placebo-controlled study.
Sign Up to like & getrecommendations! Published in 2021 at "Urology"
DOI: 10.1016/j.urology.2021.12.018
Abstract: OBJECTIVE To evaluate the additional effects of mirabegron to alpha-1 adrenergic antagonist on lower urinary tract symptoms of patients who underwent 125I-brachytherapy for prostate cancer. METHODS Patients who underwent 125I-brachytherapy for prostate cancer (cT1-cT3aN0M0) in a… read more here.
Keywords: months 125i; brachytherapy; prostate cancer; 125i brachytherapy ... See more keywords